Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

More American teenagers now use the weight-loss drug Wegovy, as doctors and families grow more comfortable with the treatment ...

Long Islanders, doctors and industry experts weigh in on medicines like Ozempic and Wegovy — how they work, what they ...

The former workers cited various reasons why they think Novo was cautious: its conservative culture and history of investing ...

The alert comes amid some patients accessing GLP-1RAs through unregulated channels, where safety information is often not ...

Previous clinical studies suggested that - when combined with changes to their diet, exercise and behavioural support - ...

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...

Now, let's return to our question: Should you invest $1,000 in Lilly right now? The shares are trading for 34 times forward ...

The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

That’s up from a rate of 9.9 prescriptions per 100,000 in 2023, the first full year that Wegovy was available to children ...